5-Amino-1MQ vs Semaglutide
A side-by-side research comparison of 5-Amino-1MQ and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-Amino-1MQ | Semaglutide |
|---|---|---|
| Full name | 5-Amino-1-Methylquinolinium (NNMT Inhibitor) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Inhibits NNMT enzyme, preventing methylation and degradation of nicotinamide. Increases intracellular NAD+ pools, activates sirtuins, and reduces fat cell size without affecting food intake. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 173.2 Da | 4,114 Da |
| Half-life | 8-12 hours | 7 days (168 hours) |
| Bioavailability | High (oral) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 50-100 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Oral (capsule) | Subcutaneous injection |
5-Amino-1MQ reported benefits
- Increased cellular energy metabolism
- Reduced fat cell size
- Elevated NAD+ levels
- Does not suppress appetite
- Improved muscle stem cell function
- Oral convenience
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.